Cover Image

Not for Sale

View/Hide Left Panel

Sanchez, Y., I.Ionescu-Matiu, II, J.T.Sparrow, J.L.Melnick, and G.R. Dreesman. 1982. Immunogenicity of conjugates and micelles of synthetic hepatitis B surface antigen peptides. Invervirol. 18(4): 209–213.

Schatz, G.C. 1983. Personal communication, Centers for Disease Control, Atlanta, Ga.

Schatz, G.C., M.A.Kane, and D.P.Francis. In press. The economic effects of hepatitis B in the United States.

Scolnick, E.M., A.A.McLean, D.J.West, W.J.McAleer, W.J.Miller, and E.B.Buynak. 1984. Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA. JAMA 251(21):2812–2815.

Schweitzer, I.L., J.W.Mosley, M.Aschavai, V.M.Edwards, and L.V. Overby. 1973. Factors influencing neonatal infection by hepatitis B virus. Gastroenterology 65(2):277–283.

Seeff, L.B. 1982. The efficacy of and place for HBIG in the prevention of type B hepatitis. Pp. 585–595 in Viral Hepatitis: 1981 International Symposium, W.Szmuness, H.J.Alter, and J.E.Maynard, eds. Philadelphia: The Franklin Institute.

Smith, G.L., M.Mackett, and B.Moss. 1983. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature 302 (5908):490–495.

Stevens, C.E. 1983. No increased incidence of AIDS in recipients of hepatitis B vaccine. N. Engl. J. Med. 308(19):1163–1164.

Stevens, C.E., R.P.Beasley, J.Tsui, and W.C.Lee. 1975. Vertical transmission of hepatitis B antigen in Taiwan. N. Engl. J. Med. 292(15):771–774.

Stevens, C.E., H.J.Alter, P.E.Taylor, E.A.Zang, E.J.Harley, W. Szmuness, and the Dialysis Vaccine Trial Study Group. In press (a). Hepatitis B vaccine in hemodialysis patients: immunogenicity and efficacy. N. Engl. J. Med.

Stevens, C.E., P.E.Taylor, M.J.Tong, P.T.Toy, and G.N.Vyas. In press (b). Hepatitis B vaccine: an overview. In Viral Hepatitis: 1984 Symposium, G.N.Vyas, J.L.Dienstag, and J.H.Hoofnagle, eds. Philadelphia: The Franklin Institute.

Szmuness, W., C.E.Stevens, E.J.Harley, E.A.Zang, W.R.Oleszko, D.C. William, R.Sadovsky, J.N.Morrison, and A.Kellner. 1980. Hepatitis B vaccine. Demonstration of efficacy in a controlled clinical trial in a high risk population in the United States. N. Engl. J. Med. 303:833–841.

Szmuness, W., C.E.Stevens, E.J.Harley, E.A.Zang, H.J.Alter, P.E. Taylor, A.DeVera, G.T.S.Chen, A.Kellner, and The Dialysis Vaccine Trial Study Group. 1982. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N. Engl. J. Med. 307(24):1481–1486.

Valenzuela, P., P.Gray, M.Quiroga, J.Zaldivar, H.M.Goodman, and W.J.Rutter. 1979. Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen. Nature 280(5725):815–819.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement